Long-term treatment with rituximab in severe juvenile idiopathic arthritis-associated uveitis

Abstract

Rituximab may be a promising effective treatment option for refractory uveitis associated with JIA leading to long-term quiescence of uveitis, particularly for patients who have not previously responded to other biologic therapies.